Web Analytics
Lupuzor 2017

Lupuzor 2017

<

Sylviane Muller with Lupuzor

1:12 AM - 21 Dec 2017

ImmuPharma $IMM says more than a quarter of patients have now completed phase III lupus

New Phase 3 Data Continues to Support ImmuPharma's Lupuzor as Safe Lupus Treatment

Alerte Trading **** on Twitter: "ImmuPharma $IMM Update on Lupuzor™ Pivotal Phase III Study #lupus #lupuzor… "

ImmuPharma $IMM initiates preparation of Lupuzor's™ regulatory submissions #lupus #lupuzor

For further information click here

Gold-standard lupus treatment Lupuzor begins phase III trial – The New Economy

#IMM+2% 50p “#IMMUPHARMA on fast track to #Lupuzor approval”: analysis from our Hd of Research, Vadim Alexandre http://bit.ly/2vmpqNu pic.twitter.com/ ...

Developing innovative drugs for serious medical conditions

#IMM $IMM #IMMUPHARMA+6% £1.81 #Lupuzor #PHARMA #INVESTING @lupussurvivors #Lupus usually develops between ages 15 and 44 and it lasts a lifetime.

ImmuPharma confident of topline results from Phase III Lupuzor trial this quarter

Auto-immune diseases

Under the bonnet1

Lanstead provides £5m to AIM Quoted ImmuPharma to support the pivotal Phase III clinical trial of Lupuzor™

Sylviane Muller (France)

Sylviane Muller (France), nominated for the European Inventor Award 2017 in the Research category

Lupuzor safety profile 'holding up' - ImmuPharma's Tim McCarthy updates on Phase III study

ImmuPharma Completes Pivotal Phase 3 Trial of Its Lupus Therapy Lupuzor

ImmuPharma

2017 and lupus research

ImmuPharma Expects Top-Line Results of Lupuzor Phase 3 Trial by Mid-April

muller-gallery5

The chart of IMM is shown above in my normal format. Earnings per share (EPS) are shown in the window below the price. The rapid rise of EPS in July 2017 ...

lupuzor

Immupharma Plc

Sylviane Muller - Treating lupus by targeting T-cells (ceremony)

Download figure ...

stucture, http://www.ama-assn.org/ama1/pub/upload/mm/365/forigerimod.pdf

ImmuPharma recruits patients for Phase III study of Lupuzor – pharmaceutical daily news

Lupus Phase 3 Clinical Trial of Lupuzor to Treat Disease Now Enrolling People in Europe and

Lupus Drug Candidate Lupuzor Pivotal Phase 3 Clinical Trial Doses First European Patients

Promising Lupus Therapy Beginning Phase 3 Clinical Testing

Download figure ...

LUPUZOR

Immupharma pleased with Lupuzor trial progress - laboratorysecondfloor opt - Immupharma pleased with Lupuzor trial progress

2 replies 1 retweet 3 likes

'We have absolutely no side effect profile in Lupuzor at all' says ImmuPharma chairman

Noble Insight raises ImmuPharma valuation to 230 pence after successful Phase Lupuzor II-b trial

Alerte Trading ****

ImmuPharma says last patient dosed in Phase III clinical trial of lupus treatment, Lupuzor™

www.frontiersin.org

0 replies 4 retweets 1 like

A glance at some of the clinical trial results with Lupuzor™ showing improvement in the condition of Lupus patients.

Immupharma Chairman presents to investors at the Biotech Capital Conference

Immupharma boss says Lupuzor trial recruitment “going well”

Modeling ...

www.frontiersin.org

BROKER SEES MULTI-BILLION POTENTIAL FOR LUPUZOR

Investigators meeting, December 2015, Paris Lupuzor's™ pivotal phase III trial - ImmuPharma

it's the little things

ImmuPharma Plc | Gallery Suite | Master Investor Show 2017

Lupus LA 2017 LA Patient Conference Video

Developing innovative drugs for serious medical conditions

logo

ImmuPharma And Simbec-Orion Collaborate And Start Pivotal Phase III Lupuzor™ Study

Immupharma 'looking forward and planning for success' with Lupuzor

Existing treatments offer marginal efficacy while leading to significant side-effects. Lupuzor™ – a potential treatment for ...

Lupuzor could treat a number of diseases, says creator

www.frontiersin.org

Immupharma sets up US$14mln funding for Lupuzor trial

Significant evidence in support of LupuzorTM

Sylviane Muller (France), nominated for the European Inventor Award 2017 in the Research category

www.frontiersin.org

muller-gallery2

Frontiers | Capability of neutrophils to form NETs is not directly influenced by a CMA-targeting peptide | Immunology

Lupuzor: Novo tratamento para Lúpus pode ser aprovado

action_lupuzor

Exciting start to 2018 for ImmuPharma with pivotal data 'weeks away'

community, see

... 12.

ImmuPharma wraps up Phase IIb of Lupuzor trials, results 'encouraging'

Sylviane Muller - Treating lupus by targeting T-cells

muller-gallery4

autoantibody production

ImmuPharma & Cenkos flag positive Lupuzor trial

Lupus Patients Much More Likely to Develop Dementia, Study Suggests

ImmuPharma PLC ...

Why investors are considering ImmuPharma, ahead of phase III data release

Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children | NEJM

Download figure ...

Immupharma (LSE: IMM)

PLAG1 and USF2 Co-regulate Expression of Musashi-2 in Human Hematopoietic Stem and Progenitor Cells

body, breathing room, surviving the holidays

conkers

hCDR1 gets EU patent

Figure 2

Cells 06 00016 g005 550

Cells 06 00016 g004 550

Lupus Patients with High Disease Activity Show 'Significant Improvement' After Taking Atacicept

Lupuzor Symposium, June 2016 Lupuzor Inventor, Prof. Sylviane Muller - DirectorsTalk